文献速递冠心病血脂与心血管预防

脂蛋白(a)浓度与心血管疾病及糖尿病风险

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes.
PubMed 文献 · J Am Coll Cardiol · 2019-12-09

基于143,087名冰岛人的病例对照研究显示,Lp(a)摩尔浓度而非载脂蛋白(a)大小决定冠心病等心血管风险,且Lp(a)浓度与冠心病风险呈剂量依赖性关联。Lp(a)浓度最低10%者2型糖尿病风险增加,而将浓度最高20%人群的Lp(a)降至人群中位数预计可降低冠心病风险且不增加糖尿病风险。

要点

  • Lp(a)摩尔浓度是影响心血管疾病风险的属性,而非apo(a)大小。
  • Lp(a)浓度最低10%与2型糖尿病风险增加相关。
  • 将浓度最高20%人群的Lp(a)降至人群中位数预计可降低冠心病风险且不增加糖尿病风险。

核心结论

  • Lp(a)摩尔浓度是影响心血管疾病风险的属性,而非载脂蛋白(a)大小。
  • 低Lp(a)浓度(最低10%)增加2型糖尿病风险。
  • 将浓度最高20%人群的Lp(a)降至人群中位数预计可降低冠心病风险且不增加2型糖尿病风险。

研究设计与样本

  • 病例对照研究,纳入143,087名有遗传信息的冰岛人,其中冠心病17,715例、2型糖尿病8,734例。
  • 使用实测和基因推断的Lp(a)摩尔浓度、KIV-2重复数(决定apo(a)大小)及LPA剪接变异进行分析。

主要发现

  • Lp(a)摩尔浓度与冠心病风险呈剂量依赖性关联,并与外周动脉疾病、主动脉瓣狭窄、心力衰竭和寿命相关。
  • Lp(a)摩尔浓度完全解释了Lp(a)与冠心病的关联,与apo(a)大小无残余关联。
  • 功能丧失突变纯合子携带者Lp(a)极低或缺失,其2型糖尿病风险增加。

临床怎么用

  • 评估心血管风险时应关注Lp(a)摩尔浓度而非apo(a)大小。
  • 对Lp(a)浓度最高20%的人群,药物降低Lp(a)至人群中位数可能降低冠心病风险且不增加2型糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular diseases that has no established therapy. The attribute of Lp(a) that affects cardiovascular risk is not established. Low levels of Lp(a) have been associated with type 2 diabetes (T2D). OBJECTIVES: This study investigated whether cardiovascular risk is conferred by Lp(a) molar concentration or apolipoprotein(a) [apo(a)] size, and whether the relationship between Lp(a) and T2D risk is causal. METHODS: This was a case-control study of 143,087 Icelanders with genetic information, including 17,715 with coronary artery disease (CAD) and 8,734 with T2D. This study used measured and genetically imputed Lp(a) molar concentration, kringle IV type 2 (KIV-2) repeats (which determine apo(a) size), and a splice variant in LPA associated with small apo(a) but low Lp(a) molar concentration to disentangle the relationship between Lp(a) and cardiovascular risk. Loss-of-function homozygotes and other subjects genetically predicted to have low Lp(a) levels were evaluated to assess the relationship between Lp(a) and T2D. RESULTS: Lp(a) molar concentration was associated dose-dependently with CAD risk, peripheral artery disease, aortic valve stenosis, heart failure, and lifespan. Lp(a) molar concentration fully explained the Lp(a) association with CAD, and there was no residual association with apo(a) size. Homozygous carriers of loss-of-function mutations had little or no Lp(a) and increased the risk of T2D. CONCLUSIONS: Molar concentration is the attribute of Lp(a) that affects risk of cardiovascular diseases. Low Lp(a) concentration (bottom 10%) increases T2D risk. Pharmacologic reduction of Lp(a) concentration in the 20% of individuals with the greatest concentration down to the population median is predicted to decrease CAD risk without increasing T2D risk.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes. J Am Coll Cardiol. 2019. PMID: 31865966. doi:10.1016/j.jacc.2019.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。